<DOC>
	<DOC>NCT02484911</DOC>
	<brief_summary>The purpose of the study is to mainly evaluate the efficacy and safety of aprepitant in combination with olanzapine ,palonosetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly or moderately emetogenic chemotherapy.</brief_summary>
	<brief_title>Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting</brief_title>
	<detailed_description>Eligible patients will be randomized to receive different antiemetic regimens . In the experimental group,patients will receive aprepitant,olanzapine ,palonosetron and dexamethasone .In the other group,patients will accept the same dose of aprepitant ,palonosetron and dexamethasone .During the treatment, any grade of nausea and vomiting should be recorded in order to evaluate the complete response rate of CINV,nausea patients will be measured by a visual analogue scale (VAS) ,other adverse events should be recorded as well.</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>1. 18 years of age or older 2. Histologically or cytologically confirmed malignant disease 3. Accept chemotherapy for the first time 4. Patients who will receive high emetogenic cancer chemotherapy (HEC) (cisplatin&gt;=70mg/m2,adriamycin in combination with cyclophosphamide ,cyclophosphamide&gt;=1500mg/m2,adriamycin&gt;60mg/m2,epirubicin&gt;90mg/m2,dacarbazine，ifosfamide&gt;=2g/m2) or moderate emetogenic chemotherapy cancer (carboplatin&gt;=300mg/m2,cyclophosphamide&gt;=6001000mg/m2,adriamycin&gt;50mg/m2) 5. Written informed consent 1. Pregnant or breastfeeding 2. Uncontrolled psychosis history 3. Inability or unwillingness to understand or cooperate with study procedures 4. Central nervous system tumors primary or secondary 5. Concurrent abdominal radiotherapy 6. History of uncontrolled diabetes mellitus 7. Patients of prostatic hyperplasia ，paralytic ileus，narrow feet glaucoma. 8. Known cardiac arrhythmia, uncontrolled congestive heart failure ,or acute myocardial infarction with the previous six month 9. Preexisting nausea or vomiting 10. Inadequate hematological function and abnormal liver and renal function. 11. History of sensitivity to olanzapine 12. Concurrent application of quinolone antibiotic therapy 13. Treatment with another antipsychotic agent such as risperidone,quetiapine, clozapine,phenothiazine,or butyrophenone for 30 days prior to or during the chemotherapy. 14. Cytochrome P450 3A4 substrates within 7 days (terfenadine, cisapride, astemizole, pimozide) 15. Concurrent application of systemic corticosteroids 16. Active infection or gastrointestinal dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>chemotherapy nausea vomiting</keyword>
</DOC>